Abstract
Background: This study aimed to evaluate the possible effects of Toxoplasma gondii infection on breast cancer through affecting the serum and expression gene level of programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) in breast cancer patients from Thi-qar province, Iraq.
Methods: This case-control study was involved 150 patients suffering from breast cancer (BC) who were referring to general hospitals of Thi-Qar province between July to September 2023 and 150 healthy patients (non-BC). Enzyme-linked immunosorbent test (ELISA) kit was used to evaluate the anti-Toxoplasma IgG and the serum level of PD-1 and PDL-1. Furthermore, the expression level of PD-1 and PDL-1 was measured through Real-time PCR.
Results: Among 150 breast cancer patients, 71 patients (47.3%) and 25 (16.6%) of healthy subjects exhibited seropositivity for anti-T. gondii IgG antibodies, resepectively. We found that the serum level and the gene expression level of PD-1 and PDL-1 were significantly higher among BC patients seropositive for T. gondii compared with BC patients who were seronegative for T. gondii antibodies (p<0.05).
Conclusion: These results indicated that T. gondii may play a role in the occurrence and even progression of cancer probably by elevating levels of PD-1 and PDL-1 genes. However, further studies are required to confirm these findings.
Full text article
References
Saadatnia G, Golkar M. A review on human toxoplasmosis. Scand J Infect Dis. 2012 Nov;44(11):805-14. doi: 10.3109/00365548.2012.693197.
Mukhopadhyay D, Arranz-Solís D, Saeij JPJ. Influence of the Host and Parasite Strain on the Immune Response During Toxoplasma Infection. Front Cell Infect Microbiol. 2020 Oct 15;10:580425. doi: 10.3389/fcimb.2020.580425.
Rostami A, Riahi SM, Contopoulos-Ioannidis DG, Gamble HR, Fakhri Y, Shiadeh MN, Foroutan M, Behniafar H, Taghipour A, Maldonado YA, Mokdad AH, Gasser RB. Acute Toxoplasma infection in pregnant women worldwide: A systematic review and meta-analysis. PLoS Negl Trop Dis. 2019 Oct 14;13(10):e0007807. doi: 10.1371/journal.pntd.0007807.
Molan A, Nosaka K, Hunter M, Wang W. Global status of Toxoplasma gondii infection: systematic review and prevalence snapshots. Trop Biomed. 2019 Dec 1;36(4):898-925
Molan A, Nosaka K, Hunter M, Wang W. Global status of Toxoplasma gondii infection: systematic review and prevalence snapshots. Trop Biomed. 2019 Dec 1;36(4):898-925.
Anvari D, Sharif M, Sarvi S, Aghayan SA, Gholami S, Pagheh AS, Hosseini SA, Saberi R, Chegeni TN, Hosseininejad Z, Daryani A. Seroprevalence of Toxoplasma gondii infection in cancer patients: A systematic review and meta-analysis. Microb Pathog. 2019 Apr;129:30-42. doi: 10.1016/j.micpath.2019.01.040.
Zhang N, Tu J, Wang X, Chu Q. Programmed cell death-1/programmed cell death ligand-1 checkpoint inhibitors: differences in mechanism of action. Immunotherapy. 2019 Apr;11(5):429-441. doi: 10.2217/imt-2018-0110.
Kornepati AVR, Vadlamudi RK, Curiel TJ. Programmed death ligand 1 signals in cancer cells. Nat Rev Cancer. 2022 Mar;22(3):174-189. doi: 10.1038/s41568-021-00431-4. Epub 2022 Jan 14. Erratum in: Nat Rev Cancer. 2022 Mar;22(3):190. doi: 10.1038/s41568-022-00445-6.
Khan IA, Ouellette C, Chen K, Moretto M. Toxoplasma: Immunity and Pathogenesis. Curr Clin Microbiol Rep. 2019 Mar;6(1):44-50. doi: 10.1007/s40588-019-0114-5.
Gocher AM, Workman CJ, Vignali DAA. Interferon-γ: teammate or opponent in the tumour microenvironment? Nat Rev Immunol. 2022 Mar;22(3):158-172. doi: 10.1038/s41577-021-00566-3.
Ajoedi A, Al Azhar M, Nadliroh S, Hartini S, Andalusia R, Witarto AB. The mRNA expression profile of PD-1 and PD-L1 in peripheral blood of colorectal cancer patients. Indonesian Journal of Cancer. 2019 Oct 16;13(3):80-5. https://doi.org/10.33371/ijoc.v13i3.670.
Fisch D, Clough B, Frickel EM. Human immunity to Toxoplasma gondii. PLoS Pathog. 2019 Dec 12;15(12):e1008097. doi: 10.1371/journal.ppat.1008097.
Caner A. Toxoplasma gondii could have a possible role in the cancer mechanism by modulating the host's cell response. Acta Trop. 2021 Aug;220:105966. doi: 10.1016/j.actatropica.2021.105966.
Azab Hameed F, Khalaf AK. The effect of infection with Toxoplasma gondii in inducing interferon-gamma in breast cancer patients. Arch Razi Inst. 2024 Feb 1;79(1):138-143. doi: 10.32592/ARI.2024.79.1.138.
Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992 Nov;11(11):3887-95. doi: 10.1002/j.1460-2075.1992.tb05481.x.
Syn NL, Teng MWL, Mok TSK, Soo RA. De-novo and acquired resistance to immune checkpoint targeting. Lancet Oncol. 2017 Dec;18(12):e731-e741. doi: 10.1016/S1470-2045(17)30607-1. PMID: 29208439.
Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK, Sharpe AH. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med. 2009 Dec 21;206(13):3015-29. doi: 10.1084/jem.20090847.
Kalim M, Iqbal Khan MS, Zhan J. Programmed cell death ligand-1: A dynamic immune checkpoint in cancer therapy. Chem Biol Drug Des. 2020 Jun;95(6):552-566. doi: 10.1111/cbdd.13677.
Al-Muskakeh, M. K., Yaseen, A. N., & Aldabagh, M. A. (2022). Assessment of Soluble PD-1 and PD-L1 in Iraqi Women Patients with Breast Cancer with Toxoplasmosis. Indian Journal of Forensic Medicine & Toxicology, 16(1): 1395-1404. https://doi.org/10.37506/ijfmt.v16i1.17692
Sadoon MM, Khalaf AK. Toxoplasma Gondii Related Programmed Cell Death (Pd1 and Pd-L1) in Patients with Diabetes Mellitus. University of Thi-Qar Journal of Medicine, 2023; 26(2): 313-319.
Atwan FK, Ali WR, Ghazi HF. An Essential Role of PD-1/PDL-1 In Placental of Aborted Women With Toxoplasmosis, Annals of Tropical Medicine and Public Health 2021; 24:570-576. http://dx.doi.org/10.36295/ASRO.2021.24603
Xiao J, Li Y, Rowley T, Huang J, Yolken RH, Viscidi RP. Immunotherapy targeting the PD-1 pathway alleviates neuroinflammation caused by chronic Toxoplasma infection. Sci Rep. 2023 Jan 23;13(1):1288. doi: 10.1038/s41598-023-28322-8.
Fife BT, Pauken KE. The role of the PD-1 pathway in autoimmunity and peripheral tolerance. Ann N Y Acad Sci. 2011 Jan;1217:45-59. doi: 10.1111/j.1749-6632.2010.05919.x.
Saçar MD, Bağcı C, Allmer J. Computational prediction of microRNAs from Toxoplasma gondii potentially regulating the hosts' gene expression. Genomics Proteomics Bioinformatics. 2014 Oct;12(5):228-38. doi: 10.1016/j.gpb.2014.09.002.
Thirugnanam S, Rout N, Gnanasekar M. Possible role of Toxoplasma gondii in brain cancer through modulation of host microRNAs. Infect Agent Cancer. 2013 Feb 8;8(1):8. doi: 10.1186/1750-9378-8-8.
He JJ, Ma J, Wang JL, Xu MJ, Zhu XQ. Analysis of miRNA expression profiling in mouse spleen affected by acute Toxoplasma gondii infection. Infect Genet Evol. 2016 Jan;37:137-42. doi: 10.1016/j.meegid.2015.11.005.
Assim MM, Saheb EJ. Serum Levels of Il-12 and Il-23 in Breast Cancer Patients Infected with Toxoplasma gondii: A Case-Control Study. Iran J Parasitol. 2020 Oct-Dec;15(4):466-474. doi: 10.18502/ijpa.v15i4.4850.
Esquivel-Velázquez M, Ostoa-Saloma P, Palacios-Arreola MI, Nava-Castro KE, Castro JI, Morales-Montor J. The role of cytokines in breast cancer development and progression. J Interferon Cytokine Res. 2015 Jan;35(1):1-16. doi: 10.1089/jir.2014.0026.
Ye HM, Lu MJ, Liu Q, Lin Y, Tang LY, Ren ZF. Beneficial Effect of Toxoplasma gondii Infection on the Prognosis of Breast Cancer Was Modified by Cytokines. Clin Epidemiol. 2023 Apr 24;15:469-481. doi: 10.2147/CLEP.S408182.
Authors
Copyright (c) 2024 Archives of Breast Cancer
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright©. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International License, which permits copy and redistribution of the material in any medium or format or adapt, remix, transform, and build upon the material for any purpose, except for commercial purposes.